This is the supplier profile page of ALKERS PHARMA, where buyers can explore products, connect directly with the supplier for pricing inquiries.
1.1
Khasra No. 349 Kha Aashiana, Sahaspur
1 inquiries
Add Favorite
Report Supplier
Business Description
November 11, 2024
Alkermes to Participate in Two Upcoming Investor Conferences
November 07, 2024
Alkermes Highlights Presentations From Across Neuroscience Portfolio at Key Fall 2024 Scientific Conferences
October 24, 2024
Alkermes plc Reports Third Quarter 2024 Financial Results
Our most recent Corporate Responsibility Report, highlighting activities that took place in 2023, showcases Alkermes' commitment to acting as a responsible corporate citizen across a range of policies, programs and practices.
Our employees' dedication to patients and our communities is foundational to our culture. Hear how our team members contribute to building an organization dedicated to creating real impact.
We are honored to be recognized as an employer of choice in the life sciences industry. Visit our Awards & Recognition page to see the latest accolades bestowed on Alkermes, based on the results of a third-party survey shared with our U.S.-based employees.
Visit our Awards & Recognition page
Click to view our interactive pipeline
Olanzapine and samidorphan
Schizophrenia and Bipolar I Disorder (Pediatric)
Olanzapine and samidorphan is a once-daily, oral atypical antipsychotic drug approved for adults in the U.S.
Olanzapine and samidorphan is currently being evaluated for pediatric use in a phase 3 study. For more information about this study, please visit enlightenyouthstudy.com (U.S. audiences only) or clinicaltrials.gov/study/NCT.
Idiopathic Hypersomnia
ALKS 2680 is an investigational, oral orexin 2 receptor agonist in development as a once-daily treatment for narcolepsy type 1, narcolepsy type 2 and idiopathic hypersomnia.
ALKS 2680 is currently being evaluated in Vibrance-1, a phase 2 study in adults with narcolepsy type 1, and Vibrance-2, a phase 2 study in adults with narcolepsy type 2.
For more information about these studies, please visit vibrancestudies.com (for U.S. audiences only) or the respective clinicaltrials.gov listings:
Neuroscience Indications
Neuroscience Indications
Additional orexin 2 receptor agonists are in discovery and preclinical research for the treatment of other neurological and psychiatric disorders.
Business Overview
Avg Response Time
≤ 1h
Total inquiries received
1
Trade Capabilities
Business Terms
Trade Ability
